...
首页> 外文期刊>American Journal of Pathology >Mutation and Expression Analyses Reveal Differential Subcellular Compartmentalization of PTEN in Endocrine Pancreatic Tumors Compared to Normal Islet Cells
【24h】

Mutation and Expression Analyses Reveal Differential Subcellular Compartmentalization of PTEN in Endocrine Pancreatic Tumors Compared to Normal Islet Cells

机译:与正常胰岛细胞相比,突变和表达分析揭示了内分泌胰腺肿瘤中PTEN的亚细胞区隔分化

获取原文
获取原文并翻译 | 示例
           

摘要

The pathogenesis of sporadic endocrine pancreatic tumors (EPTs) is still primarily unknown. Comparative genomic hybridization studies revealed loss of 10q in a significant number (nine of 31) of EPTs. The tumor suppressor gene PTEN lies on 10q23, and so, is a candidate to play some role in EPT pathogenesis. Germline PTEN mutations are found in Cowden and Bannayan-Riley-Ruvalcaba syndromes, whereas somatic mutations and deletions are found in a variety of sporadic cancers. The mutation and expression status of PTEN in EPTs has not yet been examined. Mutation analysis of the entire coding region of PTEN including splice sites was performed in 33 tumors, revealing one tumor with somatic L182F (exon 6). Loss of heterozygosity of the 10q23 region was detected in eight of 15 informative malignant (53%) and in none of seven benign EPTs. PTEN expression was assessed in 24 available EPTs by immunohistochemistry using a monoclonal anti-PTEN antibody. Of these 24, 23 tumors showed strong immunoreactivity for PTEN. Only the EPTs with PTEN mutation lacked PTEN protein expression. Although normal islet cells always exhibited predominantly nuclear PTEN immunostaining, 19 of 23 EPTs had a predominantly cytoplasmic PTEN expression pattern. Exocrine pancreatic tissue was PTEN-negative throughout. PTEN mutation is a rare event in malignant EPTs and PTEN protein is expressed in most (23 of 24) EPTs. Thus, intragenic mutation or another means of physical loss of PTEN is rarely involved in the pathogenesis of EPTs. Instead, either an impaired transport system of PTEN to the nucleus or some other means of differential compartmentalization could account for impaired PTEN function. Loss of heterozygosity of the 10q23 region is a frequent event in malignant EPTs and might suggest several hypotheses: a different tumor suppressor gene in the vicinity of PTEN might be principally involved in EPT formation; alternatively, 10q loss, including PTEN, seems to be associated with malignant transformation, but the first step toward neoplasia might involve altered subcellular localization of PTEN.
机译:散发性内分泌胰腺肿瘤(EPTs) 的发病机制仍主要未知。比较基因组杂交 研究表明,在大量EPT中(9个 31个)EPT丢失10q。抑癌基因PTEN位于10q23上,因此 因此是在EPT发病机理中起作用的候选基因。在Cowden和Bannayan-Riley-Ruvalcaba 综合征中发现了Germline PTEN突变,而在各种散发性癌症中发现了体细胞突变和缺失 。尚未检查EPT中PTEN的突变和表达 状态。对33个肿瘤进行了包括剪接位点在内的PTEN整个编码区的突变分析,发现其中1个肿瘤具有体细胞L182F (外显子6)。在15例信息性恶性肿瘤中,有8例(53%)检测到10q23区杂合性缺失(sup> ),而7例良性EPT均未检测到。使用单克隆抗PTEN抗体通过免疫组织化学评估了24种可用EPT中的PTEN表达。 在这24个肿瘤中,有23个肿瘤显示出对PTEN的强免疫反应性。 只有具有PTEN突变的EPT缺乏PTEN蛋白表达。 尽管正常的胰岛细胞总是表现出主要的核 PTEN免疫染色,但23株EPT中有19个的细胞质PTEN < / sup>表达模式。外分泌胰腺组织始终为PTE​​N阴性。 PTEN突变是恶性EPT中罕见的事件,PTEN蛋白 在大多数(24个中的23个)EPT中表达。因此,EPT的发病机理很少涉及基因内突变 或另一种PTEN的物理丧失方式。取而代之的是,PTEN到核的转运系统受损或其他一些差异化分隔的方式都可能导致PTEN功能受损。 杂合性损失10q23区域中的一个是恶性EPT中的常见事件 ,并可能提出几个假设:PTEN附近的另一个 肿瘤抑制基因可能主要是 参与EPT的形成;或者,包括 PTEN在内的10q丢失似乎与恶性转化有关, ,但向肿瘤形成的第一步可能涉及改变PTEN的亚细胞 定位。

著录项

  • 来源
    《American Journal of Pathology》 |2000年第4期|1097-1103|共7页
  • 作者单位

    From the Department of Pathology,University of Zürich, Zurich, Switzerland|the Clinical Cancer Genetics and Human Cancer Genetics Programs,Comprehensive Cancer Center, and Division of Human Genetics, Department of Internal Medicine, The Ohio State University, Columbus, Ohio;

    From the Department of Pathology,University of Zürich, Zurich, Switzerland;

    From the Department of Pathology,University of Zürich, Zurich, Switzerland;

    From the Department of Pathology,University of Zürich, Zurich, Switzerland;

    From the Department of Pathology,University of Zürich, Zurich, Switzerland;

    the Department of Cancer Biology,Massachusetts Institute of Technology, Cambridge, Massachusetts;

    From the Department of Pathology,University of Zürich, Zurich, Switzerland;

    the Clinical Cancer Genetics and Human Cancer Genetics Programs,Comprehensive Cancer Center, and Division of Human Genetics, Department of Internal Medicine, The Ohio State University, Columbus, Ohio|and the Cancer Research Campaign Human Cancer Genetics Research Group,University of Cambridge, Cambridge, United Kingdom;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号